On July 13, 2024, Maxvax’s recombinant herpes zoster (Shingles) vaccine (CHO cell) finished the enrollment of its first human subject for Phase III clinical trial in China’s Henan Province, marking the launch of the vaccine’s Phase III clinical trial. Maxvax’s Shingles vaccine adopts recombinant protein technology and carries independently developed new adjuvant system MA105. It is the first innovative vaccine with composite adjuvant system with independent intellectual property rights to enter Phase Ⅲ clinical trial in China. The results of Phase Ⅰ and Ⅱ clinical trials show that it has good safety, tolerability, and immunogenicity. Phase Ⅲ clinical trial will further verify the safety, immunogenicity, and protective efficacy of the vaccine in a large sample of people to provide key data for the marketing application of the product.

About Shingles vaccine

Shingles, also known as herpes zoster, is a viral disease characterized by a painful skin rash with blisters in a localized area. The disease is most seen in people over the age of 50. Right now, herpes zoster vaccination is the best way to effectively reduce the risk of shingles and postherpetic neuralgia.

Unlike the live attenuated herpes zoster vaccine which is no longer used in countries with more advanced vaccine development technology, Maxvax’s Shingles vaccine with the new adjuvant system can activate stronger cellular immunity and improve the vaccine’s immune efficacy in the elderly and people with impaired immune systems, providing better and longer-lasting protection to the vaccinated population.

The Shingles vaccine independently developed by Maxvax is the first domestic herpes zoster vaccine with a new adjuvant system with independent intellectual property rights to enter Phase III clinical trials. By researching and developing adjuvant molecules and adjuvant systems with independent intellectual property rights, Maxvax is expected to be among the first-tier companies of the global biopharmaceutical industry and to provide safer and more effective prevention options for patients around the world.

About Maxvax

Since its start, Maxvax has worked continually to overcome the hardest part of the technology of new vaccine adjuvants and has therefore realized the independent control of the supply chain of adjuvant raw materials, laying out a diversified product pipelines in the field of infectious diseases and oncology. Up to now, three vaccine candidates are under clinical studies.

With a steadfast commitment to innovation, Maxvax will continuously be dedicated to enhancing public health andemphasizing its role as a collaborative partner in the global health community.